CMS's Lumirix® Secures Initial Vitiligo Prescriptions Across China
Event summary
- CMS's Lumirix® (ruxolitinib phosphate cream) achieved initial prescriptions for vitiligo patients across 30 provincial-level regions in China, covering approximately 1,000 medical institutions and 1,300 offline drugstores, as well as JD.com's e-commerce platform.
- The product, marketed as Opzelura® in the U.S., Europe, and Canada, is the first topical JAK inhibitor approved in China for vitiligo treatment.
- Lumirix® received its Drug Registration Certificate on January 30, 2026, following a streamlined approval process supported by China's regulatory reforms.
- The rapid commercialization of Lumirix® reflects strong product operation capabilities of CMS and Dermavon, as well as robust support from regulatory authorities and business partners.
The big picture
CMS's successful launch of Lumirix® underscores the growing importance of targeted therapies in dermatology and the strategic advantage of China's regulatory reforms in accelerating patient access to innovative drugs. The rapid commercialization of Lumirix® highlights the potential for CMS to strengthen its leadership in skin health and expand its market presence in China and Southeast Asia. The product's approval and initial prescriptions mark a significant milestone in the treatment of vitiligo, a condition affecting approximately 10.3 million patients in China.
What we're watching
- Regulatory Efficiency
- The pace at which China's regulatory reforms accelerate the approval and commercialization of innovative drugs will impact CMS's ability to bring new therapies to market quickly.
- Market Penetration
- Whether CMS can sustain the rapid adoption of Lumirix® across more regions and medical institutions in China, given the competitive landscape and existing treatment options.
- Commercialization Strategy
- How CMS leverages its integrated healthcare ecosystem and partnerships to enhance the accessibility and reach of Lumirix®, particularly in emerging markets.
Related topics